Brief: Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For Review Of NDA Resubmission For Treatment Of UCDS

MindMaze Therapeutics Holding SA

28/07/2022 13:36

July 28 (Reuters) - Acer Therapeutics Inc  ACER.O :
    * ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE FDA
ACCEPTANCE FOR REVIEW OF NDA RESUBMISSION FOR ACER-001 FOR
TREATMENT OF UCDS
    * ACER THERAPEUTICS INC - FDA DESIGNATED NDA AS A CLASS 2
RESUBMISSION AND SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA)
TARGET ACTION DATE OF JANUARY 15, 2023.

Source text for Eikon:  ID:nGNX5CBZ3X 
Further company coverage:  ACER.O 

 (Reporting by Kannaki Deka)
 ((Kannaki.Deka@thomsonreuters.com;))